Roberto Bolli, M.D., D.Sc. (Hon) FAHA, FACC

• Professor of Medicine, Physiology and Biophysics
• Jewish Hospital Heart and Lung Institute Distinguished Chair in Cardiology
• Director, Institute of Molecular Cardiology
• Distinguished University Scholar

UofL Physicians Outpatient Center
401 East Chestnut Street, Ste. 310
Louisville, KY 40202

502-852-1837- Academic Office
502-588-7010 - Patient Appointments

Get To Know Dr. Bolli

Featured Publications

• Nong Y, Guo Y, Ou Q, Gumpert A, Tomlin A, Zhu X, Bolli R. PU.1 inhibition does not attenuate cardiac function deterioration or fibrosis in a murine model of myocardial infarction. Mol Cell Biochem. 2023 Apr;478(4):927-937. doi: 10.1007/s11010-022-04561-7. Epub 2022 Sep 17. PMID: 36114991; PMCID: PMC10091869.
• Bolli R, Solankhi M, Tang XL, Kahlon A. Cell therapy in patients with heart failure: a comprehensive review and emerging concepts. Cardiovasc Res. 2022 Mar 16;118(4):951-976. doi: 10.1093/cvr/cvab135. PMID: 33871588; PMCID: PMC8930075.
• Bolli R, Tang XL. New insights into cardioprotection, gained by adopting the CAESAR standards of rigor. Basic Res Cardiol. 2022 Nov 11;117(1):57. doi: 10.1007/s00395-022-00964-1. PMID: 36367590.
• Taylor DA, Chacon-Alberty L, Sampaio LC, Hierro MGD, Perin EC, Mesquita FCP, Henry TD, Traverse JH, Pepine CJ, Hare JM, Murphy MP, Yang PC, March KL, Vojvodic RW, Ebert RF, Bolli R; Cardiovascular Cell Therapy Research Network (CCTRN). Recommendations for nomenclature and definition of cell products intended for human cardiovascular use. Cardiovasc Res. 2022 Aug 24;118(11):2428-2436. doi: 10.1093/cvr/cvab270. PMID: 34387303; PMCID: PMC9400434.
• Tang XL, Wysoczynski M, Gumpert AM, Li Y, Wu WJ, Li H, Stowers H, Bolli R. Effect of intravenous cell therapy in rats with old myocardial infarction. Mol Cell Biochem. 2022 Feb;477(2):431-444. doi: 10.1007/s11010-021-04283-2. Epub 2021 Nov 16. PMID: 34783963; PMCID: PMC8896398.
• Bolli R, Tang XL. Clinical trials of cell therapy for heart failure: recent results warrant continued research. Curr Opin Cardiol. 2022 May 1;37(3):193-200. doi: 10.1097/HCO.0000000000000956. PMID: 35612934; PMCID: PMC9178910.
• Bolli R. CAESAR's legacy: a new era of rigor in preclinical studies of cardioprotection. Basic Res Cardiol. 2021 May 20;116(1):33. doi:10.1007/s00395-021-00874-8. PMID: 34018051; PMCID: PMC8137617.
• Bolli R, Mitrani RD, Hare JM, Pepine CJ, Perin EC, Willerson JT, Traverse JH, Henry TD, Yang PC, Murphy MP, March KL, Schulman IH, Ikram S, Lee DP, O'Brien C, Lima JA, Ostovaneh MR, Ambale-Venkatesh B, Lewis G, Khan A, Bacallao K, Valasaki K, Longsomboon B, Gee AP, Richman S, Taylor DA, Lai D, Sayre SL, Bettencourt J, Vojvodic RW, Cohen ML, Simpson L, Aguilar D, Loghin C, Moyé L, Ebert RF, Davis BR, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. Eur J Heart Fail. 2021 Apr;23(4):661-674. doi: 10.1002/ejhf.2178. Epub 2021 Apr 13. PMID: 33811444; PMCID: PMC8357352.
• Bolli R, Perin EC, Willerson JT, Yang PC, Traverse JH, Henry TD, Pepine CJ, Mitrani RD, Hare JM, Murphy MP, March KL, Ikram S, Lee DP, O'Brien C, Durand JB, Miller K, Lima JA, Ostovaneh MR, Ambale-Venkatesh B, Gee AP, Richman S, Taylor DA, Sayre SL, Bettencourt J, Vojvodic RW, Cohen ML, Simpson LM, Lai D, Aguilar D, Loghin C, Moyé L, Ebert RF, Davis BR, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial. JACC CardioOncol. 2020 Nov;2(4):581-595. doi: 10.1016/j.jaccao.2020.09.001. Epub 2020 Dec 22. PMID: 33403362; PMCID: PMC7781291.
• Wysoczynski M, Bolli R. A realistic appraisal of the use of embryonic stem cell-based therapies for cardiac repair. Eur Heart J. 2020 Jul 1;41(25):2397-2404. doi: 10.1093/eurheartj/ehz787. PMID: 31778154; PMCID: PMC7327535.